TQB-2858 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TQB-2858’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TQB-2858 is under development for the treatment of advanced malignant solid tumors, advanced metastatic pancreatic cancer, recurrent or metastatic advanced endometrial carcinoma, alveolar soft tissue sarcoma, pleomorphic sarcoma, classic osteosarcoma, Ewing sarcoma, chondrosarcoma, dedifferentiated liposarcoma, cervical cancer and hematological tumors and recurrent/metastatic nasopharyngeal cancer. It is administered through intravenous drip. It acts by targeting PDL1 and transforming growth factor beta (TGFb).
Chia Tai Tianqing Pharmaceutical Group overview
Chia Tai Tianqing Pharmaceutical Group (CTTQ) manufactures and commercializes anticancer drugs. The company produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, engineering novel liver, cardiovascular, cancer, mental, anesthesia, urinary, and others. The company operates through its technology and research and development centers in Jiangsu. CTTQ is headquartered in Lianyungang, Nanjing, China.
For a complete picture of TQB-2858’s drug-specific PTSR and LoA scores, buy the report here.